Literature DB >> 16174247

Postoperative vaginal brachytherapy alone is the treatment of choice for grade 1-2, stage IC endometrial cancer.

M Cengiz1, A K Singh, P W Grigsby.   

Abstract

The aim was to determine outcome and toxicity in grade 1-2, FIGO stage IC endometrial cancer patients treated with external beam radiotherapy plus vaginal cuff brachytherapy or vaginal cuff brachytherapy alone. Between 1986 and 1999, a total of 132 patients were diagnosed with FIGO stage IC endometrial carcinoma. The median age was 67.5 years (range, 36-88). Median follow-up was 54 months (range, 6-157). Grade 1 disease was present in 64 patients, grade 2 in 45 patients, and grade 3 in 23 patients. Patients with grade 3 disease usually received external radiotherapy and were excluded from this analysis. Of the patients with grade 1-2 disease, 31 received brachytherapy alone and 78 received both external radiotherapy and brachytherapy. Ten (8%) patients experienced failure. Isolated pelvic relapse occurred in five patients. Three patients experienced both distant and local relapse. Two patients had isolated distant relapse. Nine failures occurred in patients treated with both external radiotherapy and brachytherapy. Only one failure occurred in those treated with brachytherapy alone. Overall survival and disease-free survival at 5 years were 85% and 92%, respectively. For those treated with both external radiotherapy and brachytherapy, 5-year locoregional control was 95%. For those treated with brachytherapy alone, 5-year locoregional control was 96.4%. There was no significant survival or local control difference between the two groups. Nine patients (9%) treated with both external radiotherapy and brachytherapy developed Radiation Therapy Oncology Group grade 3-4 toxicity. No patient treated with vaginal cuff brachytherapy alone developed grade 3-4 toxicity (P < 0.001). In patients with well-differentiated (grade 1-2) stage IC endometrial cancer, external beam radiotherapy plus brachytherapy versus vaginal cuff brachytherapy alone achieved equivalent local control and survival. However, vaginal cuff brachytherapy alone produced significantly less toxicity.

Entities:  

Mesh:

Year:  2005        PMID: 16174247     DOI: 10.1111/j.1525-1438.2005.00156.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

1.  Could S6K1 immunopositivity be used to distinguish early and advanced stages of endometrioid endometrial adenocarcinoma?

Authors:  İsmet Gün; Özkan Özdamar; Zafer Küçükodacı; Murat Muhçu; Dilaver Demirel
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-09-01

2.  Prospective clinical trial of bladder filling and three-dimensional dosimetry in high-dose-rate vaginal cuff brachytherapy.

Authors:  Alexandra J Stewart; Robert A Cormack; Hang Lee; Li Xiong; Jorgen L Hansen; Desmond A O'Farrell; Akila N Viswanathan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-18       Impact factor: 7.038

3.  Bladder (ICRU) dose point does not predict urinary acute toxicity in adjuvant isolated vaginal vault high-dose-rate brachytherapy for intermediate-risk endometrial cancer.

Authors:  Lucas Gomes Sapienza; Antonio Aiza; Maria José Leite Gomes; Michael Jenwei Chen; Antonio Cassio de Assis Pellizzon; David B Mansur; Glauco Baiocchi
Journal:  J Contemp Brachytherapy       Date:  2015-10-13

4.  Retrospective Analysis of Intravaginal Brachytherapy in Adjuvant Treatment of Early Endometrial Cancer.

Authors:  Paweł Cisek; Dariusz Kieszko; Izabela Kordzińska-Cisek; Elżbieta Kutarska; Ludmiła Grzybowska-Szatkowska
Journal:  Biomed Res Int       Date:  2018-02-21       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.